| Identification | Back Directory | [Name]
1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE | [CAS]
404009-46-7 | [Synonyms]
AMA37
DNA-PK INHIBITOR V
ARYLMORPHOLINE ANALOG 37
1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE | [Molecular Formula]
C17H18NO3 | [MDL Number]
MFCD09037528 | [MOL File]
404009-46-7.mol | [Molecular Weight]
284.33 |
| Hazard Information | Back Directory | [Definition]
ChEBI: [2-hydroxy-4-(4-morpholinyl)phenyl]-phenylmethanone is a member of benzophenones. | [Biological Activity]
AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively[1][2].
AMA-37 inhbits PI3K poorly[2].AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to overcome G2 arrest (Ρ < 0.05)[3].Inhibition of DNA-PK with AMA37 leads to radiosensitization[3]. | [References]
[1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [2]. Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59. [3]. Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92. |
|
|